Risks to Sponsors Developing and Running Their Own DCT Technology

With decentralized clinical trials (DCTs) becoming more prevalent and both sites and patients showing their enthusiasm and support for the model, sponsors are seeking to expand their use in their portfolios of clinical trials. To keep up with the changes, many sponsors are evaluating their DCT technology needs as they look to license, purchase, or build their own DCT technology systems.

Scrip, in partnership with IQVIA, presents a look at what it really takes to run a “home grown” DCT solution, and examines the complexities to consider when licensing existing DCT technology.

Whitepaper

Complete the form below to download the content.

* - marks a required field

Email Address

First Name

Last Name

Address

City

Country

State

Post Code

Phone

Answer the following questions about your organization below:

Company Name

How many people are employed by your organization?

What is your company's revenue?

In which industry do you work?

Job Title

Job Level

By clicking ‘Submit’ you agree to our Terms of Use. We take your privacy seriously. For more information please read our Privacy Policy.